Amarin Corp Plc (AMRN)

[zz1]

RE : Cardiovascular outcomes.

Based on large outcome lipid trials in the last decade or more, the focus among lipidologists has been a movement from LDL to non-HDL, the latter showing a very strong correlation coefficient with Apo-B. The current level of outcomes data with inflammatory markers ( despite the results Jupiter and Jelis )has certainly not reached the level of scientific evidence to expect NCEP to include these as targets for current standards of care. Therefore, prescribing decisions by physicians (and sub-specialists such as myself)have and continue to be driven by the total body of cinical evidence, and when this level of evidence reaches a critical mass then it is adopted by the NCEP, ACC, and NLA etc and becomes part of "Current Guidelines" and "Standards of Care". Despite the growth of basic and clinical research with athero-inflammatory markers, at the present time we do have have any target CRP goals provided in any of the present "Guidelines" to achieve with our patients with increased cardiovascular risk.
Therefore, the clinical message to physicians with regard to Vascepa in my mind is very clear and powerful:
1) 45% reduction of Triglycerides when baseline Triglycerides are are 750 or more.
2) 65% reduction of Triglycerides when Vascepa is combined with Statins in patients with very Triglycerides. This is a unique scientific observation and clinically very relevant.
3)The above achieved without an increase in LDL Cholesterol - another unique finding.
4)Excellent safety profile.